Clinical Trial Update: Efficacy, Safety and Tolerability of a Novel Malathion Formulation in Patients 2 Years and Older With Head Lice [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating efficacy, safety and tolerability of a novel malathion formulation in patients aged 2 years and older with pediculosis (head lice).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pediculosis

Drugs mentioned

• Malathion (novel formulation) (malathion)

Snippet

Sponsor: Sun Pharmaceutical Industries, Inc. | Conditions: Pediculosis | Phase 3 | Status: COMPLETED | Results posted: 2014-06-13